Researchers are encouraged by initial study results of a new eye drop that has been developed to treat early to moderate age-related cataracts.
Results of the clinical trial were published in the American Journal of Ophthalmology. The Phase 1/2 clinical trial was conducted at six locations in the United States and included 111 patients. The eye drops work by breaking up degraded protein complexes that cause the lens of the eye to cloud, which creates cataracts.
Researchers evaluated the efficacy of the eye drop (C-KAD) and results demonstrated that 66.7% of the patients had clinically remarkable improvement in contrast sensitivity compared to 35% of those who were in the placebo group after 4 months. None of the study subjects reported adverse events. Researchers also noted best-corrected visual acuity and improved lens transparency among study participants.
While the initial results are promising, researchers note that larger prospective clinical trials are necessary to validate these results.
